Big Congratulations to Tvardi Therapeutics on the successful completion of its merger with Cara Therapeutics, which officially created a Nasdaq-listed, clinical-stage biopharmaceutical company under the ticker TVRD, effective April 16, 2025!
We at the AIM-HI Accelerator Fund are incredibly proud to have supported the translational research efforts out of the MD Anderson Cancer Center that formed Tvardi. As a non-profit organization committed to supporting bold, innovative oncology startups, it’s inspiring to see Tvardi’s STAT3-targeting technology take a major step closer to delivering impact for patients with fibrosis-driven diseases and cancer.
This milestone is a powerful reminder of what early-stage support can make possible. Congratulations again to the Tvardi team on this exciting new chapter! Read more: https://ir.tvarditherapeutics.com/news-releases/news-release-details/tvardi-therapeutics-announces-closing-merger-cara-therapeutics.
- Merger creates a Nasdaq-listed, clinical-stage biopharmaceutical company – Tvardi Therapeutics – developing novel treatments targeting STAT3 to treat fibrosis-driven diseases
- Tvardi shares to begin trading under the symbol “TVRD” on April 16, 2025
- Post-transaction cash and cash equivalents expected to fund operations into the second half of 2026
- Tvardi anticipates reporting topline data from two Phase 2 clinical programs utilizing its STAT3 inhibitor, TTI-101, including its lead program in idiopathic pulmonary fibrosis (IPF), in the second half of 2025, followed by its program in hepatocellular carcinoma (HCC) in the first half of 2026
